Biotherapy (Dordrecht, Netherlands) - JoVE Visualize

Showing results (11-20 of 322) with videos related to

Pageof 33

Sort By:

Biotherapy (Dordrecht, Netherlands)|January 1, 1990

Effects of interleukin-2 (IL-2) on human plasma lipid, lipoprotein, and C-reactive proteinI B Rosenzweig, D A Wiebe, J A Hank, et al.

Biotherapy (Dordrecht, Netherlands)|April 29, 1998

HLA-DR/DQ transgenic, class II deficient mice as a novel model to select for HSP T cell epitopes with immunotherapeutic or preventative vaccine potentialA Geluk, V Taneja, K E van Meijgaarden, et al.

Biotherapy (Dordrecht, Netherlands)|April 29, 1998

Mucosal modulation of immune responses to heat shock proteins in autoimmune arthritisD Bonnin, S Albani

Biotherapy (Dordrecht, Netherlands)|April 29, 1998

Antigen-specific therapies in multiple sclerosisJ M van Noort

Biotherapy (Dordrecht, Netherlands)|January 1, 1997

Treatment of head and neck cancers with BRMs--prolongation of survivalT Yoshida, T Saeki, Y Aoyama, et al.

Biotherapy (Dordrecht, Netherlands)|January 1, 1997

The in vitro effect of new muramyl peptide derivatives on cytotoxic activity of NK (natural killer) cells from hamsters bearing Ab Bomirski melanomaD Sosnowska, A Mysliwski, K Dzierzbicka, et al.

Biotherapy (Dordrecht, Netherlands)|January 1, 1992

Polyclonal activation of human lymphocytes and induction of cytotoxic lymphocytes by streptococcal preparationsT Sato, M Fujii, H Satoh, et al.

Biotherapy (Dordrecht, Netherlands)|January 1, 1992

The promotive effect of interleukin 4 with interleukin 2 in the proliferation of tumor-infiltrating lymphocytes from patients with malignant tumorT Tsunoda, H Tanimura, H Yamaue, et al.

Biotherapy (Dordrecht, Netherlands)|January 1, 1992

Supernatants derived from CD8+ lymphocytes activated by mycobacterial fractions inhibit cytokine production. The role of interleukin-6G Sussman, A A Wadee

Biotherapy (Dordrecht, Netherlands)|January 1, 1989

A phase I trial of recombinant tumor necrosis factor (rTNF) administered by continuous intravenous infusion in patients with disseminated malignancyJ E Schwartz, P Scuderi, C Wiggins, et al.

Pageof 33

Showing results (11-20 of 322) with videos related to

Sort By:

Pageof 33

Biotherapy (Dordrecht, Netherlands)|January 1, 1990

Effects of interleukin-2 (IL-2) on human plasma lipid, lipoprotein, and C-reactive proteinI B Rosenzweig, D A Wiebe, J A Hank, et al.

Biotherapy (Dordrecht, Netherlands)|April 29, 1998

HLA-DR/DQ transgenic, class II deficient mice as a novel model to select for HSP T cell epitopes with immunotherapeutic or preventative vaccine potentialA Geluk, V Taneja, K E van Meijgaarden, et al.

Biotherapy (Dordrecht, Netherlands)|April 29, 1998

Mucosal modulation of immune responses to heat shock proteins in autoimmune arthritisD Bonnin, S Albani

Biotherapy (Dordrecht, Netherlands)|April 29, 1998

Antigen-specific therapies in multiple sclerosisJ M van Noort

Biotherapy (Dordrecht, Netherlands)|January 1, 1997

Treatment of head and neck cancers with BRMs--prolongation of survivalT Yoshida, T Saeki, Y Aoyama, et al.

Biotherapy (Dordrecht, Netherlands)|January 1, 1997

The in vitro effect of new muramyl peptide derivatives on cytotoxic activity of NK (natural killer) cells from hamsters bearing Ab Bomirski melanomaD Sosnowska, A Mysliwski, K Dzierzbicka, et al.

Biotherapy (Dordrecht, Netherlands)|January 1, 1992

Polyclonal activation of human lymphocytes and induction of cytotoxic lymphocytes by streptococcal preparationsT Sato, M Fujii, H Satoh, et al.

Biotherapy (Dordrecht, Netherlands)|January 1, 1992

The promotive effect of interleukin 4 with interleukin 2 in the proliferation of tumor-infiltrating lymphocytes from patients with malignant tumorT Tsunoda, H Tanimura, H Yamaue, et al.

Biotherapy (Dordrecht, Netherlands)|January 1, 1992

Supernatants derived from CD8+ lymphocytes activated by mycobacterial fractions inhibit cytokine production. The role of interleukin-6G Sussman, A A Wadee

Biotherapy (Dordrecht, Netherlands)|January 1, 1989

A phase I trial of recombinant tumor necrosis factor (rTNF) administered by continuous intravenous infusion in patients with disseminated malignancyJ E Schwartz, P Scuderi, C Wiggins, et al.

Pageof 33